Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Stage Identification and Engagement to Reduce the Duration of Untreated Psychosis: Evaluating the Impact of Screening and Systematic Communication

NCT05509998 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT05509998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05509998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Stage Identification and Engagement to Reduce the Duration of Untreated Psychosis: Evaluating the Impact of Screening and Systematic Communication
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Not applicable
Overall status
Recruiting
Start date
May 1, 2023
Completion date
April 30, 2027
Enrollment
912 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical high risk for psychosis (chr), first episode psychosis (fep)